MedTrace Logo

Comparison of Perennial and Preseasonal Subcutaneous Immunotherapy

NCT01555736 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2012-03-21

No results posted yet for this study

Summary

Specific immunotherapy, which involves the administration of allergic extracts to patients with symptoms of allergic disorder, is the leading therapeutical tool of modern allergology. According to the latest studies immunotherapy not only reduces symptoms' severity but also may modify the course of allergic disease by reducing the risk of new sensitisations and development of more advanced stages of the disease.It has been hypothesized basing on clinical observation that perennial immunotherapy is more effective and safer in comparison to preseasonal immunotherapy. The aim of the study was to compare the effect of perennial and preseasonal immunotherapy on rhinoconjunctivitis symptoms and safety of both treatments.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

DRUG

grass (80%) and rye (20%) pollens allergoids

comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.

Sponsors & Collaborators

  • Allergopharma GmbH & Co. KG

    collaborator INDUSTRY

  • Medical University of Lodz

    lead OTHER

Principal Investigators

  • Piotr Kuna, MD, PhD · Department of Internal Diseases, Asthma and allergy, Medical University of Lodz

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-01-31
Primary Completion
2006-07-31
Completion
2006-09-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01555736 on ClinicalTrials.gov